ATE306481T1 - Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen - Google Patents

Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen

Info

Publication number
ATE306481T1
ATE306481T1 AT00928712T AT00928712T ATE306481T1 AT E306481 T1 ATE306481 T1 AT E306481T1 AT 00928712 T AT00928712 T AT 00928712T AT 00928712 T AT00928712 T AT 00928712T AT E306481 T1 ATE306481 T1 AT E306481T1
Authority
AT
Austria
Prior art keywords
pyrazolecarboxamide
diseases
treat obesity
obesity
treat
Prior art date
Application number
AT00928712T
Other languages
English (en)
Inventor
Cheryl P Kordik
Timothy W Lovenberg
Allen B Reitz
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE306481T1 publication Critical patent/ATE306481T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00928712T 1999-05-12 2000-05-02 Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen ATE306481T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13384299P 1999-05-12 1999-05-12
PCT/US2000/011903 WO2000069849A1 (en) 1999-05-12 2000-05-02 Pyrazole carboxamides useful for the treatment of obesity and other disorders

Publications (1)

Publication Number Publication Date
ATE306481T1 true ATE306481T1 (de) 2005-10-15

Family

ID=22460538

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00928712T ATE306481T1 (de) 1999-05-12 2000-05-02 Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen

Country Status (8)

Country Link
US (2) US6291476B1 (de)
EP (1) EP1177188B1 (de)
AR (1) AR023957A1 (de)
AT (1) ATE306481T1 (de)
AU (1) AU778393B2 (de)
CA (1) CA2373510A1 (de)
DE (1) DE60023128T2 (de)
WO (1) WO2000069849A1 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
AU2002221222A1 (en) * 2000-12-04 2002-06-18 Biovitrum Ab Novel method and use
SE0004462D0 (sv) * 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
UY27450A1 (es) * 2001-09-24 2003-04-30 Bayer Corp Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
JP2005507932A (ja) * 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換５−員窒素含有複素環
AU2003245773A1 (en) 2002-02-15 2003-09-04 Glaxo Group Limited Vanilloid receptor modulators
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1601666A2 (de) 2002-07-02 2005-12-07 Schering Corporation Neuropeptid y y5 rezeptor antagonisten
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1433788A1 (de) * 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazol-Derivate als Faktor Xa Inhibitoren
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1606289B1 (de) 2003-02-14 2009-12-02 Glaxo Group Limited Carboxamidderivate
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
JP2006525355A (ja) * 2003-05-01 2006-11-09 アボット・ラボラトリーズ ナトリウムチャンネルモジュレーターとしてのピラゾール−アミドおよびスルホンアミド
EP1628661A2 (de) * 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Vr1-rezeptor-modulatoren
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
WO2005011677A1 (en) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
US20050113576A1 (en) * 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1734963A4 (de) 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
WO2006032851A1 (en) * 2004-09-20 2006-03-30 Biolipox Ab Pyrazole compounds useful in the treatment of inflammation
CN101094689B (zh) 2004-11-01 2013-06-12 安米林药品有限责任公司 治疗肥胖以及肥胖相关疾病和病症的方法
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EP1853610A1 (de) * 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl-benzamid-derivate als sirtuin-modulatoren
MX2007013595A (es) 2005-05-04 2008-01-24 Renovis Inc Compuestos heterociclicos fusionados y composiciones y usos de estos.
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7897589B2 (en) * 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (de) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente.
EP1757587A1 (de) * 2005-07-15 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Substituierte Pyrazolinderivate, ihre Herstellung und Verwendung als Arzneimittel
EP1743892A1 (de) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
DK1910384T3 (da) * 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
EP2330125A3 (de) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybridpolypeptide mit auswählbaren Eigenschaften
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
EP1940842B1 (de) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
EP1944301A4 (de) 2005-10-27 2012-01-04 Msd Kk Neue benzoxathiinderivate
EP1943234A1 (de) * 2005-10-31 2008-07-16 Biolipox AB Triazolverbindungen als lipoxygenaseinhibitoren
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009513692A (ja) * 2005-11-01 2009-04-02 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
PL2046787T3 (pl) 2006-08-01 2011-10-31 Glaxo Group Ltd Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4
CA2661898A1 (en) * 2006-08-25 2008-02-28 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
CA2672196A1 (en) 2006-12-20 2008-07-03 Abbott Laboratories Antagonists of the trpv1 receptor and uses thereof
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
EP2136639B1 (de) 2007-04-02 2016-03-09 Evotec AG Pyrid-2-yl-anellierte heterocyclische verbindungen, und ihre zusammensetzungen und verwendungen
PT2139334E (pt) 2007-04-17 2013-10-02 Evotec Ag Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
HRP20151052T1 (xx) 2007-07-19 2015-11-06 H. Lundbeck A/S Peteroäślani heterocikliäśki amidi i srodne tvari
ES2408384T3 (es) * 2007-07-27 2013-06-20 Bristol-Myers Squibb Company Nuevos activadores de glucoquinasa y procedimientos de uso de los mismos
WO2009058348A1 (en) * 2007-11-01 2009-05-07 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
MX2010005186A (es) * 2007-11-08 2010-05-27 Sirtris Pharmaceuticals Inc Tiazolopiridinas solubilizadas.
CA2715835C (en) 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
EP2264026A4 (de) 2008-03-06 2012-03-28 Msd Kk Alkylaminopyridinderivate
EP2489660A1 (de) * 2008-03-20 2012-08-22 Abbott Laboratories Verfahren zum Herstellen von Mitteln für das zentrale Nervensystem, die TRPV1-Antagonisten sind
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2151234A1 (de) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmazeutische Formulierung mit einer CB1-Rezeptorverbindung in einer festen Lösung und/oder festen Dispersion
EP2319841A1 (de) 2008-07-30 2011-05-11 Msd K.K. (5-gliedriges)-(5-gliedriges) oder (5-gliedriges)-(6-gliedriges) kondensiertes ringcycloalkylaminderivat
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (de) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidinderivate und verfahren zu deren anwendung
BRPI0922435A2 (pt) 2008-12-19 2018-09-11 Sirtris Pharmaceuticals Inc "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
WO2010111059A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3 receptor antagonists for treatment of pain
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
ES2969565T3 (es) 2015-09-30 2024-12-13 Max Planck Ges Zur Foerderung Derwissenschaften E V Derivados heteroarílicos como inhibidores de la sepiapterina reductasa
CN108713019B (zh) 2016-03-17 2021-06-15 豪夫迈·罗氏有限公司 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (de) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetische spirochromanverbindungen
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2021032935A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
WO2021046515A1 (en) * 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
BR112022010082A2 (pt) 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
BR112023002957A2 (pt) 2020-08-18 2023-04-04 Merck Sharp & Dohme Llc Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
KR20250010152A (ko) 2022-02-14 2025-01-20 액센트 테라퓨틱스, 인크. Rna 헬리카제 dhx9의 억제제 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0041322A1 (de) * 1980-05-30 1981-12-09 Beecham Group Plc m-Pyrazolylamidotetramisol-Derivate, Verfahren zur Herstellung dieser Verbindungen, sie enthaltende Zusammensetzungen sowie ihre Verwendung bei der Behandlung der Helminthiasis
JPS6425763A (en) * 1987-04-24 1989-01-27 Mitsubishi Chem Ind Pyrazoles and insecticide and acaricide containing said pyrazoles as active ingredient
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
US5900415A (en) 1994-11-07 1999-05-04 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
AU692977B2 (en) 1994-11-07 1998-06-18 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5668151A (en) 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
DE69719544T2 (de) 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
CA2274593A1 (en) 1996-12-13 1998-06-18 Banyu Pharmaceutical Co., Ltd. Novel aminopyrazole derivatives
CA2274594C (en) 1996-12-16 2006-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
CA2284218A1 (en) * 1997-03-18 1998-09-24 Smithkline Beecham P.L.C. Substituted isoquinoline derivatives and their use as anticonvulsants
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.

Also Published As

Publication number Publication date
US6291476B1 (en) 2001-09-18
AU4690600A (en) 2000-12-05
US20020058816A1 (en) 2002-05-16
CA2373510A1 (en) 2000-11-23
DE60023128D1 (de) 2006-02-23
EP1177188A1 (de) 2002-02-06
EP1177188B1 (de) 2005-10-12
US6511998B2 (en) 2003-01-28
AU778393B2 (en) 2004-12-02
AR023957A1 (es) 2002-09-04
DE60023128T2 (de) 2006-07-06
WO2000069849A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60026627D1 (de) Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60012138D1 (de) Gerät zur behandlung von fibrillation
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE279386T1 (de) Retinoide zur behandlung von emphysem
EP1117431A4 (de) Behandlung von acidose
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60305400D1 (de) Anlage zur Behandlung von Produkten und dazugehörige Datenerfassungseinheit
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
DE60036723D1 (de) Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties